Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

Date publication

septembre 2020

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland

Tous les auteurs :
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault PA, Le Garff G, Falchero L, Berard H, Schott R, Saulnier P, Chouaid C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32888454

Résumé

Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer.

Référence

Lancet Oncol.. 2020 Sep;21(9):1224-1233